PATENT CLAIM ANALYSIS

Application Number: 15947370
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "052000"]

Abstract:
The present disclosure provides a combination therapy to treat neurodegenerative diseases. In one embodiment, Alzheimer's disease is treated with an orally administered mitochondria stimulant, neuro protective antioxidant that crosses the blood brain barrier and is supplemented with a drug that promotes hippocampal neurogenesis. The combination therapy of a mitochondria stimulant, a brain available antioxidant and a neurogenesis agonist, may be employed to prevent, inhibit or treat neurodegenerative diseases that have a root cause of inflammation, oxidative stress, followed by free radical biologic macromolecule destruction, and eventually cell death, such as Parkinson's, age related Dementia, Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS).

Claim (Index 13):
The method of  claim 12  wherein the neurodegenerative disease is Alzheimer's disease.

Metadata:
- Claim Count in Document: 6.0
- Percentile: 91.0
- Lexical Diversity: 1.50617
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15058903', '13493514', '11058441', '15146255', '12942785']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.5640053734211942
- 35 USC 102 Novelty (BERT): 0.506593737796793
- Combined Prediction Score: 0.5582642098587541
- Mean Citation Score: 187.681872
- Max Citation Score: 219.59851
- Similarity Product: 152.35029356276155

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test